Category: by journal

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease. 

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate

Drip, drip: UCLA investigation finds more image duplications

Image duplications and unsupported data continue to plague a network of cancer researchers that includes the former vice chancellor for research at the University of California, Los Angeles, James Economou.

On July 2, the editors at Cancer Research retracted a 2011 paper that Economou published as last author, saying it suffered from image duplication and unsupported figures. This is the second retraction we’re aware of to come out of an investigation by UCLA’s Office of Research Policy and Compliance that has touched this group of scientists.

Here’s the notice for “Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor–CTL Interaction,” which says the retraction comes at the request of UCLA: Continue reading Drip, drip: UCLA investigation finds more image duplications

Science journal flags cancer paper under investigation for image manipulation

Science Signaling has issued an expression of concern for a 2016 paper, citing an institutional investigation into image manipulation.

According to a spokesperson for the journal, the corresponding author, Tanya Kalin, became concerned that two images in the paper had been manipulated. Kalin then notified the research integrity officer at Cincinnati Children’s Hospital Medical Center, where she is based.

On May 9 2017, Kalin alerted the journal to the investigation. A week later, the hospital’s research integrity officer followed up with the journal, flagging the figures under question.  The journal then prepared an expression of concern (EOC) to alert readers to the issues and the institution’s investigation.  

Here’s the EOC notice for “The transcription factor FOXF1 promotes prostate cancer by stimulating the mitogen-activated protein kinase ERK5:” Continue reading Science journal flags cancer paper under investigation for image manipulation

NIH neuroscientist up to 19 retractions

Stanley Rapoport.
Source: NIH

The string of apparent bad luck continues for Stanley Rapoport.

Rapoport, a neuroscientist based at the U.S. National Institute on Aging, has lost three more papers in three journals due to the misconduct of his co-authors. By our count, these retractions bring his tally to 19 — and tie him for 21st place on our leaderboard.

The journals—Schizophrenia Research, Journal of Affective Disorders, and Biological Psychiatry— retracted the papers because the National Institutes of Health had found that one of Rapoport’s co-authors, Jagadeesh Rao, had “engaged in research misconduct by falsifying data.” Rao was corresponding author on all three papers.

According to a spokesperson for Elsevier, which publishes the journals, the Schizophrenia Research paper was retracted in July, the JAD paper in late May and the Biological Psychiatry paper in late April. The spokesperson told us that the publisher first received an email from the NIH about the misconduct findings on September 20, 2016, and that: Continue reading NIH neuroscientist up to 19 retractions

Diabetes researcher who sued to prevent retractions now has 13

A diabetes researcher who sued a publisher to protect several papers from being retracted recently received his 13th, in a prestigious gastroenterology journal.

Mario Saad, based at the University of Campinas in São Paulo, Brazil, has had a string of retractions over the past few years, including four in Diabetes after he lost a legal battle with the American Diabetes Association.

The latest retraction appears in Gastroenterology, citing possible image duplication. Saad is second-to-last author on the 2012 paper.

According to the retraction notice, the journal investigated data in several figures, and believes some were duplicated. The authors explained that the duplications resulted from inadvertently using wrong blots; still, the editors chose to retract the paper after determining they no longer had confidence in its conclusions.  

Here’s the retraction notice for “Obesity-Induced Increase in Tumor Necrosis Factor-α Leads to Development of Colon Cancer in Mice:” Continue reading Diabetes researcher who sued to prevent retractions now has 13

Want to appeal a journal’s rejection? Sure — that’ll be $700

Different journals follow different editorial policies — but we’ve never seen any charge money to authors who want to appeal an editorial decision. Until now.

Recently, a criminal justice researcher sent us links to multiple journals that charge appeal fees. For instance, the Journal of Accounting Research says authors must pay $500 for each submission — and another $500 if they want the journal to reconsider its decision to reject the paper.

Under “Appeals,” the journal writes:

Continue reading Want to appeal a journal’s rejection? Sure — that’ll be $700

Authors say patient threatened legal action after being subject of scholarly paper

A patient appears to have had a change of heart about being featured in a case report.

The patient cannot be identified in the paper published in Journal of Gastrointestinal and Liver Diseases. However, according to the retraction notice, she threatened to sue if the authors did not withdraw it. After receiving the threat, the paper’s corresponding author, Mariano Sica, told us that the authors immediately asked the journal to retract the paper.

We’ve written about similar cases where patients do not provide informed consent or withdraw it, but in this case we haven’t seen the threat ourselves.

We asked Sica if we could see the legal threat, and he said he couldn’t share it, explaining: Continue reading Authors say patient threatened legal action after being subject of scholarly paper

Nature Chemistry issues its first retraction

For the first time in its eight-year history, Nature Chemistry has retracted a paper, citing “data integrity issues.”

The 2010 paper, which explored how various iron-based molecules interact with water and ethanol, was withdrawn after the authors uncovered possible duplication in two images.

According to the retraction notice, the authors could not provide the raw data to confirm their findings and could not reproduce the figures because the experimental set-up had been dismantled. The authors subsequently requested the paper be retracted because the issues undermined “our full confidence in the integrity of the study.”

Here’s the retraction notice for “Charge transfer to solvent identified using dark channel fluorescence-yield L-edge spectroscopy”: Continue reading Nature Chemistry issues its first retraction

Nature retracts paper by stem cell scientist appealing her dismissal

Susana Gonzalez

A once-rising star in stem cell biology — who recently lost both her job and a sizable grant — has had a fourth paper retracted.

The notice — issued by Nature for a 2006 letter — cites duplicated images, and a lack of raw data to verify the findings. First author Susana Gonzalez — who was dismissed from her position at the National Center for Cardiovascular Research (CNIC) in Spain last February over allegations of misconduct — couldn’t be reached by the journal.

Here’s the full text of the retraction notice:

Continue reading Nature retracts paper by stem cell scientist appealing her dismissal

“We were devastated:” Authors retract paper after realizing they had used the wrong mice

Raymond Pasek and Maureen Gannon

Longtime readers of Retraction Watch may recall a 2011 post about a research team that retracted a paper after realizing that they had ordered the wrong mice. Maureen Gannon and Raymond Pasek of Vanderbilt University contacted us earlier this week to alert us to a similar case: Their retraction, earlier this month, of a 2016 paper from American Journal of Physiology – Endocrinology and Metabolism after discovering that “a colleague from another lab had mistakenly supplied us with the wrong transgenic mouse line.”

“We strongly believe that sharing this example will encourage other researchers to do the right thing when a mistake is discovered and promote academic integrity,” they wrote. So we asked them to answer a few questions about their experience with “Connective tissue growth factor is critical for proper β-cell function and pregnancy-induced β-cell hyperplasia in adult mice,” a paper that has been cited twice, according to Clarivate Analytics’ Web of Science. 

Retraction Watch: How, and when, did you become aware of the error? Continue reading “We were devastated:” Authors retract paper after realizing they had used the wrong mice